Cargando…
Post Transplantation Cyclophosphamide Improves Outcome of Autologous Hematopoietic Stem Cell Transplantation in Animal Model of Multiple Sclerosis
Experimental allergic encephalomyelitis (EAE) is the animal model of multiple sclerosis (MS). Autologous hematopoietic stem cell transplantation (AHSCT) has recently been recognized as the standard treatment for MS. The aim of our experiment was to investigate the effect of AHSCT with the addition o...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8238731/ https://www.ncbi.nlm.nih.gov/pubmed/34181099 http://dx.doi.org/10.1007/s00005-021-00619-4 |
_version_ | 1783714960537288704 |
---|---|
author | Kasarełło, Kaja Snarski, Emilian Sulejczak, Dorota Ciesielski, Tomasz Wiśniewska, Agnieszka Wrzesień, Robert Cudnoch-Jędrzejewska, Agnieszka |
author_facet | Kasarełło, Kaja Snarski, Emilian Sulejczak, Dorota Ciesielski, Tomasz Wiśniewska, Agnieszka Wrzesień, Robert Cudnoch-Jędrzejewska, Agnieszka |
author_sort | Kasarełło, Kaja |
collection | PubMed |
description | Experimental allergic encephalomyelitis (EAE) is the animal model of multiple sclerosis (MS). Autologous hematopoietic stem cell transplantation (AHSCT) has recently been recognized as the standard treatment for MS. The aim of our experiment was to investigate the effect of AHSCT with the addition of low-dose post-transplantation cyclophosphamide (Cy) on EAE in rats. Low dose post-transplantation Cy is used in haploidentical HSCT to reduce the risk of graft versus host disease. We hypothesized that it could bring additional benefit in autologous HSCT in autoimmune diseases. Rats with evoked EAE were treated with high dose (125 mg/kg) Cy, followed by AHSCT or high dose (125 mg/kg) Cy followed by AHSCT followed by low dose (20 mg/kg) Cy in two-time schedules—with the therapy applied during the pre-symptomatic or symptomatic phase of the disease. Both AHSCT and AHSCT with post-transplantation Cy in accordance with both time schedules reduce the intensity of the inflammatory response in the CNS, in comparison with non-treated EAE rats. The reduction of clinical symptoms was present in all AHSCT treatment protocols, however, it was significantly stronger when post-transplantation Cy was given during the symptomatic phase of the disease. AHSCT with the addition of post HSCT low dose Cy improved the results of AHSCT by not only reducing the intensity of inflammation in the CNS but also by significantly reducing the clinical symptoms in treated animals when compared to AHSCT alone. We provide an experimental rationale that the addition of post-transplantation Cy may improve the outcome of HSCT in MS. GRAPHIC ABSTRACT: [Image: see text] |
format | Online Article Text |
id | pubmed-8238731 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Springer International Publishing |
record_format | MEDLINE/PubMed |
spelling | pubmed-82387312021-07-13 Post Transplantation Cyclophosphamide Improves Outcome of Autologous Hematopoietic Stem Cell Transplantation in Animal Model of Multiple Sclerosis Kasarełło, Kaja Snarski, Emilian Sulejczak, Dorota Ciesielski, Tomasz Wiśniewska, Agnieszka Wrzesień, Robert Cudnoch-Jędrzejewska, Agnieszka Arch Immunol Ther Exp (Warsz) Original Article Experimental allergic encephalomyelitis (EAE) is the animal model of multiple sclerosis (MS). Autologous hematopoietic stem cell transplantation (AHSCT) has recently been recognized as the standard treatment for MS. The aim of our experiment was to investigate the effect of AHSCT with the addition of low-dose post-transplantation cyclophosphamide (Cy) on EAE in rats. Low dose post-transplantation Cy is used in haploidentical HSCT to reduce the risk of graft versus host disease. We hypothesized that it could bring additional benefit in autologous HSCT in autoimmune diseases. Rats with evoked EAE were treated with high dose (125 mg/kg) Cy, followed by AHSCT or high dose (125 mg/kg) Cy followed by AHSCT followed by low dose (20 mg/kg) Cy in two-time schedules—with the therapy applied during the pre-symptomatic or symptomatic phase of the disease. Both AHSCT and AHSCT with post-transplantation Cy in accordance with both time schedules reduce the intensity of the inflammatory response in the CNS, in comparison with non-treated EAE rats. The reduction of clinical symptoms was present in all AHSCT treatment protocols, however, it was significantly stronger when post-transplantation Cy was given during the symptomatic phase of the disease. AHSCT with the addition of post HSCT low dose Cy improved the results of AHSCT by not only reducing the intensity of inflammation in the CNS but also by significantly reducing the clinical symptoms in treated animals when compared to AHSCT alone. We provide an experimental rationale that the addition of post-transplantation Cy may improve the outcome of HSCT in MS. GRAPHIC ABSTRACT: [Image: see text] Springer International Publishing 2021-06-28 2021 /pmc/articles/PMC8238731/ /pubmed/34181099 http://dx.doi.org/10.1007/s00005-021-00619-4 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Original Article Kasarełło, Kaja Snarski, Emilian Sulejczak, Dorota Ciesielski, Tomasz Wiśniewska, Agnieszka Wrzesień, Robert Cudnoch-Jędrzejewska, Agnieszka Post Transplantation Cyclophosphamide Improves Outcome of Autologous Hematopoietic Stem Cell Transplantation in Animal Model of Multiple Sclerosis |
title | Post Transplantation Cyclophosphamide Improves Outcome of Autologous Hematopoietic Stem Cell Transplantation in Animal Model of Multiple Sclerosis |
title_full | Post Transplantation Cyclophosphamide Improves Outcome of Autologous Hematopoietic Stem Cell Transplantation in Animal Model of Multiple Sclerosis |
title_fullStr | Post Transplantation Cyclophosphamide Improves Outcome of Autologous Hematopoietic Stem Cell Transplantation in Animal Model of Multiple Sclerosis |
title_full_unstemmed | Post Transplantation Cyclophosphamide Improves Outcome of Autologous Hematopoietic Stem Cell Transplantation in Animal Model of Multiple Sclerosis |
title_short | Post Transplantation Cyclophosphamide Improves Outcome of Autologous Hematopoietic Stem Cell Transplantation in Animal Model of Multiple Sclerosis |
title_sort | post transplantation cyclophosphamide improves outcome of autologous hematopoietic stem cell transplantation in animal model of multiple sclerosis |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8238731/ https://www.ncbi.nlm.nih.gov/pubmed/34181099 http://dx.doi.org/10.1007/s00005-021-00619-4 |
work_keys_str_mv | AT kasarełłokaja posttransplantationcyclophosphamideimprovesoutcomeofautologoushematopoieticstemcelltransplantationinanimalmodelofmultiplesclerosis AT snarskiemilian posttransplantationcyclophosphamideimprovesoutcomeofautologoushematopoieticstemcelltransplantationinanimalmodelofmultiplesclerosis AT sulejczakdorota posttransplantationcyclophosphamideimprovesoutcomeofautologoushematopoieticstemcelltransplantationinanimalmodelofmultiplesclerosis AT ciesielskitomasz posttransplantationcyclophosphamideimprovesoutcomeofautologoushematopoieticstemcelltransplantationinanimalmodelofmultiplesclerosis AT wisniewskaagnieszka posttransplantationcyclophosphamideimprovesoutcomeofautologoushematopoieticstemcelltransplantationinanimalmodelofmultiplesclerosis AT wrzesienrobert posttransplantationcyclophosphamideimprovesoutcomeofautologoushematopoieticstemcelltransplantationinanimalmodelofmultiplesclerosis AT cudnochjedrzejewskaagnieszka posttransplantationcyclophosphamideimprovesoutcomeofautologoushematopoieticstemcelltransplantationinanimalmodelofmultiplesclerosis |